Radioactive Carbon Incorporated in Urea for H. Pylori Test
|
By LabMedica International staff writers Posted on 26 Nov 2008 |
The noninvasive test method used clinically for the diagnosis of Helicobacter pylori infection and post-eradication follow-up is the urea breath test (UBT). A probe for the bacteria has been developed by incorporating a radioactive isotope of carbon into the urea used for the test.
H. pylori produce an enzyme, urease, which catalyzes the hydrolysis of the urea molecule into ammonium and carbon dioxide. The urea contains one carbon atom that is replaced by the radioactive carbon isotope. The probe, developed by Stat Diagnostics Services (Mumbai, India), is called the Heliprobe instrument.
A Helicap (hard urea 14C) is ingested with 50 ml of water. When H. pylori are present in the stomach, urease metabolizes the C-urea releasing carbon dioxide containing the C-labeled atoms. The carbon dioxide passes through the mucosa into the blood stream and it is transported to the lungs where it is exhaled. The amount of CO2 produced in the stomach can be measured with the Heliprobe instrument.
If the patient is not infected, no metabolisation of urea will occur and therefore no CO2 is detected--the unmetabolised C urea will be excreted in the urine. If the Heliprobe system detects CO2, this is diagnostic evidence of an ongoing infection with H. pylori.
Related Links:
Stat Diagnostics Services
H. pylori produce an enzyme, urease, which catalyzes the hydrolysis of the urea molecule into ammonium and carbon dioxide. The urea contains one carbon atom that is replaced by the radioactive carbon isotope. The probe, developed by Stat Diagnostics Services (Mumbai, India), is called the Heliprobe instrument.
A Helicap (hard urea 14C) is ingested with 50 ml of water. When H. pylori are present in the stomach, urease metabolizes the C-urea releasing carbon dioxide containing the C-labeled atoms. The carbon dioxide passes through the mucosa into the blood stream and it is transported to the lungs where it is exhaled. The amount of CO2 produced in the stomach can be measured with the Heliprobe instrument.
If the patient is not infected, no metabolisation of urea will occur and therefore no CO2 is detected--the unmetabolised C urea will be excreted in the urine. If the Heliprobe system detects CO2, this is diagnostic evidence of an ongoing infection with H. pylori.
Related Links:
Stat Diagnostics Services
Latest Microbiology News
- TORCH Infection Trends Point to Need for Tailored Screening in Pregnancy
- Automated Blood Culture System Speeds Detection of Bloodstream Infections
- New Culture Medium Speeds C. difficile Resistance Detection and Reduces Costs
- Gut Microbiome Signatures Help Identify Risk of IBD Progression
- FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
- New AMR Assay Supports Rapid Infection Control Screening in Hospitals
- Diagnostic Gaps Complicate Bundibugyo Ebola Outbreak Response in Congo
- Study Finds Hidden Mpox Infections May Drive Ongoing Spread
- Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals
- Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
- Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
- Label-Free Microscopy Method Enables Faster, Quantitative Detection of Malaria
- Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
- Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
- Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
- Antibiotic Resistance Genes Found in Newborns Within Hours of Birth
Channels
Clinical Chemistry
view channel
Urinary Biomarker Assay Predicts Kidney Disease Progression Beyond Standard Measures
Many patients with type 2 diabetes and chronic kidney disease continue to experience progressive renal decline, yet conventional markers such as albuminuria and estimated glomerular filtration rate (eGFR)... Read more
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreMolecular Diagnostics
view channel
AI Tool Improves Accuracy of Cancer Liquid Biopsy for Therapy Selection
Liquid biopsy is increasingly used to guide targeted therapy by detecting tumor-derived mutations in blood, but distinguishing true tumor signals from background noise remains challenging.... Read more
Study Highlights Inherited Breast Cancer Risk Genes in Young Black Women
Early-onset breast cancer remains a significant concern, with some cases presenting as triple-negative disease, one of its most aggressive forms. Black women face disproportionately elevated risks of developing... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read morePathology
view channel
AI Pathology Tool Predicts Meningioma Recurrence from Routine Slides
Meningiomas are the most common primary brain tumors in adults, yet their course ranges from indolent to highly recurrent disease. Estimating an individual patient’s recurrence risk often requires advanced... Read more
3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
Colorectal cancer remains a leading cause of cancer death, and clinical decision-making is complicated by marked intra-tumor heterogeneity. Conventional bulk sequencing averages molecular signals across... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel
Genetic Testing Program Expands Detection of Alpha-1 Antitrypsin Deficiency
Alpha-1 Antitrypsin Deficiency (AATD) is a progressive genetic condition, the leading known genetic risk factor for chronic obstructive pulmonary disease (COPD), and a cause of liver disease in both children... Read more




.jpg)



